Key Insights

Highlights

Success Rate

79% trial completion

Published Results

66 trials with published results (22%)

Research Maturity

146 completed trials (49% of total)

Clinical Risk Assessment

Based on trial outcomes

Moderate Risk

Score: 49/100

Termination Rate

12.8%

38 terminated out of 298 trials

Success Rate

79.3%

-7.2% vs benchmark

Late-Stage Pipeline

12%

37 trials in Phase 3/4

Results Transparency

45%

66 of 146 completed with results

Key Signals

66 with results79% success38 terminated

Data Visualizations

Phase Distribution

208Total
Not Applicable (46)
Early P 1 (2)
P 1 (60)
P 2 (63)
P 3 (28)
P 4 (9)

Trial Status

Completed146
Terminated38
Unknown37
Recruiting30
Active Not Recruiting25
Enrolling By Invitation10

Trial Success Rate

79.3%

Benchmark: 86.6%

Based on 146 completed trials

Clinical Trials (298)

Showing 20 of 20 trials
NCT06128564Phase 2Active Not RecruitingPrimary

A Gene Delivery Study to Evaluate the Safety and Expression of Delandistrogene Moxeparvovec in Participants Under the Age of Four With Duchenne Muscular Dystrophy (DMD)

NCT07704099Phase 2Not Yet RecruitingPrimary

Safety and Efficacy of KER-065 in Participants With Duchenne Muscular Dystrophy

NCT03368742Phase 1Active Not RecruitingPrimary

Microdystrophin Gene Transfer Study in Adolescents and Children With DMD

NCT07287189Phase 2RecruitingPrimary

Phase 2 Study of SAT-3247 in Pediatric Ambulatory Patients

NCT06244082Phase 2Active Not Recruiting

Ph2 Open-label Study of AOC 1044 in Duchenne Muscular Dystrophy Participants With Mutations Amenable to Exon44 Skipping

NCT06817382Phase 1RecruitingPrimary

A Study to Investigate the Safety and Biodistribution of a Single Intrathecal (IT) Injection of INS1201 in Ambulatory Males With Duchenne Muscular Dystrophy (DMD)

NCT06579352Phase 2Active Not RecruitingPrimary

Phase 2 Expanded Access Study of UC-MSC in DMD Patients

NCT05933057Phase 3RecruitingPrimary

Efficacy, Safety and Tolerability of Givinostat in Non-ambulant Patients With Duchenne Muscular Dystrophy

NCT04972604CompletedPrimary

CureDuchenne Link®: A Resource for Research

NCT04281485Phase 3Active Not RecruitingPrimary

Study to Evaluate the Safety and Efficacy of PF-06939926 for the Treatment of Duchenne Muscular Dystrophy

NCT05693142Phase 2Active Not RecruitingPrimary

AFFINITY DUCHENNE: RGX-202 Gene Therapy in Participants With Duchenne Muscular Dystrophy (DMD)

NCT06564974RecruitingPrimary

Registry Study to Observe Long-term Safety of Vamorolone (AGAMREE®) in Patients With Duchenne Muscular Dystrophy-SUMMIT

NCT07160634Phase 3RecruitingPrimary

A Study of SGT-003 Gene Therapy in Ambulant Males With Duchenne Muscular Dystrophy (IMPACT DUCHENNE)

NCT03836300Not ApplicableEnrolling By Invitation

Parent and Infant Inter(X)Action Intervention (PIXI)

NCT06138639Phase 1RecruitingPrimary

A Study of SGT-003 Gene Therapy in Duchenne Muscular Dystrophy (INSPIRE DUCHENNE)

NCT05683379Active Not RecruitingPrimary

AFFINITY BEYOND: Anti-AAV8 Antibody Assessment Study of Males With DMD

NCT03655223Active Not Recruiting

Early Check: Expanded Screening in Newborns

NCT07673809Phase 1RecruitingPrimary

A Study to Evaluate the Tolerability, Safety and Efficacy of GNR-097 Gene Therapy in Pediatric Patients With Duchenne Muscular Dystrophy

NCT06280209Phase 1Active Not RecruitingPrimary

A Phase 1/2 Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of BMN 351 in Participants With Duchenne Muscular Dystrophy

NCT04626674Phase 1RecruitingPrimary

A Gene Transfer Therapy Study to Evaluate the Safety of and Expression From Delandistrogene Moxeparvovec (SRP-9001) in Participants With Duchenne Muscular Dystrophy (DMD) - Non-Ambulatory Cohort

Scroll to load more

Research Network

Activity Timeline